Bioxytran (BIXT) Stock Price & Analysis

BIXT Stock Chart & Stats

$0.02-$0.00(-11.21%)

At close: Nov 02 10:54 AM EST

Day’s Range: $0.02 - $0.02
52-Week Range: $0.02 - $0.09
Previous Close: $0.02
Volume: N/A
Average Volume (3M): 71.27K
Market Cap: $2.66M
Enterprise Value: $4.21T
Total Cash (Recent Filing): $177.38K
Total Debt (Recent Filing): $855.00K
Price to Earnings (P/E): ―
Beta: -1.52
Next Earnings: N/A
EPS Estimate: N/A
Next Dividend Ex-Date: N/A
Dividend Yield: N/A

Bioxytran News

Bioxytran reports initial clinical observations from PLICID trial

Bioxytran ( ($BIXT) ) has provided an update. On August 11, 2026, Bioxytran reported initial clinical observations from the first Chronic Inflammatory Demyelinating Polyneuropathy patient treated with its investigational galectin

2M ago8K BIXT

Bioxytran Delays Annual 10-K Filing

Bioxytran ( ($BIXT) ) has released a notification of late filing. Bioxytran, Inc. has filed a Form 12b-25 indicating a delayed filing of its Form 10-K (Yearly Report) for the

7M agoBIXT

Bioxytran Raises Capital to Advance Development and Commercialization

Bioxytran ( ($BIXT) ) has provided an announcement. Bioxytran, Inc., a clinical-stage biotechnology company developing therapies for hypoxia-related conditions and galectin-targeting technologies across viral, metabolic, and inflammatory diseases, is also

7M ago8K BIXT

Bioxytran Tightens Preferred Share Conversion Governance Rules

Bioxytran ( ($BIXT) ) has provided an update. On February 18, 2026, Bioxytran amended its Certificate of Designation for Convertible Preferred Stock, filing the change with the Nevada Secretary of

7M ago8K BIXT

Bioxytran Reports Positive ProLectin-M Phase 1b/2a COVID Trial

Bioxytran ( ($BIXT) ) has shared an update. On March 2, 2026, Bioxytran, Inc. reported positive results from a randomized, double-blind, placebo-controlled Phase 1b/2a trial of its oral antiviral ProLectin-M

8M ago8K BIXT

Bioxytran Signs Distribution Deal, Initiates Commercial Nutraceutical Shift

Bioxytran ( ($BIXT) ) has shared an update. On February 10, 2026, Bioxytran signed a commercial distribution agreement with Khoury Medical LTD for A-SUQAR, a chewable dietary supplement containing its

8M ago8K BIXT

Bioxytran Reports Strong Phase 2 Results for ProLectin-M

Bioxytran ( ($BIXT) ) has issued an announcement. On Feb. 11, 2026, Bioxytran reported positive topline data from a completed Phase 2 randomized, double-blind, placebo-controlled, dose-optimization trial of its oral

8M ago8K BIXT

Bioxytran Faces Officer Termination and Governance Dispute

An update from Bioxytran ( ($BIXT) ) is now available. On December 29, 2025, Bioxytran, Inc. terminated Mike Sheikh from his position as an officer of the company. In a

10M ago8K BIXT

Bioxytran Board Member Resigns Amid Governance Changes

Bioxytran ( ($BIXT) ) has shared an update. On December 7, 2025, Bioxytran, Inc. experienced a significant change in its governance as Anders Utter resigned from the Board of Directors

10M ago8K BIXT

Bioxytran Delays 10-K Filing Due to Audit

Bioxytran ( ($BIXT) ) has released a notification of late filing. Bioxytran, Inc. has announced a delay in filing its Form 10-K (Yearly Report) for the financial period ending December

1y agoBIXT

BIXT FAQ

What was Bioxytran’s price range in the past 12 months?

Bioxytran lowest stock price was $0.02 and its highest was $0.09 in the past 12 months.

What is Bioxytran’s market cap?

Bioxytran’s market cap is $2.66M.

When is Bioxytran’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

Is Bioxytran overvalued?

Not enough analysts have published a price target to calculate whether the price is overvalued.

Does Bioxytran pay dividends?

Bioxytran does not currently pay dividends.

What is Bioxytran’s EPS estimate?

Bioxytran’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Bioxytran have?

Bioxytran has 114,695,220 shares outstanding.

Which hedge fund is a major shareholder of Bioxytran?

Currently, no hedge funds are holding shares in BIXT

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Bioxytran

Bioxytran, Inc. is a pharmaceutical firm operating in the clinical development phase, dedicated to creating, producing, and marketing medicinal treatments for oxygen deficiency (hypoxia) in people. Its primary drug under development, BXT-25, is a small, oxygen-transporting molecule crafted from bovine hemoglobin, stabilized by a co-polymer. This compound is intended for tackling oxygen deprivation in the brain caused by strokes, as well as addressing wound hypoxia to avert tissue death and encourage recovery. Additionally, Bioxytran is advancing ProLectin-Rx, a pectin-derived polysaccharide. This substance functions by attaching to and inhibiting galectin-1, a specific galectin, to treat mild to moderate instances of Covid-19. Established in 2008, the company maintains its main office in Newton, Massachusetts.

Technical Analysis

Overall Consensus

Indicator	Bullish	Neutral	Bearish
Overall Consensus	9	1	11
Technical Analysis	6	1	2
Moving Averages	3	0	9

Technical Analysis >

Similar Stocks

Stocks similar to BIXT
Company	Price & Change	Follow
DCOYDecoy Therapeutics
OGENOragenics
MBRXMoleculin Biotech
GRIGRI Bio
AZTRAzitra Inc

Compare BIXT Stocks >

Ownership Overview

1.02% Insiders
98.98% Public Companies and Individual Investors

Detailed Ownership Overview >

Popular Stocks

Popular Stocks
Company	Price & Change	Follow
NVDANvidia
AAPLApple
MSFTMicrosoft

BIXT Stock Chart & Stats

Bioxytran News

Bioxytran reports initial clinical observations from PLICID trial

Bioxytran Delays Annual 10-K Filing

Bioxytran Raises Capital to Advance Development and Commercialization

Bioxytran Tightens Preferred Share Conversion Governance Rules

Bioxytran Reports Positive ProLectin-M Phase 1b/2a COVID Trial

Bioxytran Signs Distribution Deal, Initiates Commercial Nutraceutical Shift

Bioxytran Reports Strong Phase 2 Results for ProLectin-M

Bioxytran Faces Officer Termination and Governance Dispute

Bioxytran Board Member Resigns Amid Governance Changes

Bioxytran Delays 10-K Filing Due to Audit

BIXT FAQ

Company Description

Bioxytran

Technical Analysis

Overall Consensus

Similar Stocks

Ownership Overview

Popular Stocks

Become an Expert with TipRanks Premium